HC Wainwright & Co. Reiterates Buy on Verastem, Maintains $18 Price Target
HC Wainwright & Co. analyst Andres Y. Maldonado reiterates Verastem (NASDAQ:VSTM) with a Buy and maintains $18 price target.
Stocks · News reference
Verastem Oncology Doses First Participant In Its TARGET-D 203 Phase 2 Study Of VS-7375 To Treat Metastatic Colorectal Cancer
Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the first patient has been dosed in the TARGET-D
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
BTIG Reiterates Buy on Verastem, Maintains $18 Price Target
BTIG analyst Jeet Mukherjee reiterates Verastem (NASDAQ:VSTM) with a Buy and maintains $18 price target.
Verastem Stock Skyrockets 121% in 3 Months: Here Is Why
Verastem (VSTM) shares have surged 121% over three months, driven by accelerating sales of ovarian cancer drug Avmapki Fakzynja Co-Pack, which generated $25.1 million in Q2 2026 revenues (up 1,095% YoY), and growing optimism around VS-7375, a KRAS G12D inhibitor in phase II trials across pancreatic, lung, and colorectal cancers. The company expects VS-7375 data in October 2026 and plans FDA meetings before year-end to discuss phase III pivotal trial designs.
Verastem Oncology To Host Investor Event On October 14 To Present Initial Efficacy And Updated Data For VS-7375 In Pancreatic, Lung, And Colorectal Cancers From Ongoing TARGET-D Clinical Development Program
Investor event and webcast to be held Wednesday, October 14, 2026, at 8:00 am ETVerastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven